APRE
Aprea Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.51
−1.90%Nov 4, 2026, 13:30 UTC
Aprea Therapeutics reported third-quarter 2026 financial results, including $37.8 million in cash and cash equivalents as of September 30, 2026, and said its cash runway is expected to extend into the first quarter of 2028.
Source:Oct 16, 2026, 12:30 UTC
Aprea Therapeutics announced that it will host a virtual panel discussion on WEE1 inhibition in precision oncology on October 20, 2026, at 11 a.m. ET.
Source:Aug 12, 2026, 12:30 UTC
Aprea Therapeutics announced its financial results for the second quarter of 2026.
Source: